Objectives: aEuro,To determine whether plasma netrin-1 can be used as a diagnostic biomarker of human cancer. Materials and Methods: aEuro,A total of 300 cancer plasma samples from breast, renal, prostate, liver, meningioma, pituitary adenoma, glioblastoma, lung, pancreatic and colon cancer patients were compared against 138 control plasma samples. Netrin-1 levels were quantified by ELISA and immunohistochemistry. Results: aEuro,Plasma netrin-1 levels were significantly increased in breast, renal, prostate, liver, meningioma, pituitary adenoma, and glioblastoma cancers as compared to control samples. Discussion and Conclusion: aEuro,Our results suggest that plasma netrin-1 can be used as a diagnostic biomarker for many human cancers.